1
|
Chambon M, Herrscher C, Al Halabi D, François N, Belouzard S, Boutet S, Pham VC, Doan TMH, Séron K, Mavingui P, Litaudon M, El Kalamouni C, Apel C. New Phenolic Lipids from the Leaves of Clausena harmandiana Inhibit SARS-CoV-2 Entry into Host Cells. Molecules 2023; 28:5414. [PMID: 37513285 PMCID: PMC10384782 DOI: 10.3390/molecules28145414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 07/11/2023] [Accepted: 07/12/2023] [Indexed: 07/30/2023] Open
Abstract
Induced by the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the COVID-19 pandemic underlined the clear need for antivirals against coronaviruses. In an effort to identify new inhibitors of SARS-CoV-2, a screening of 824 extracts prepared from various parts of 400 plant species belonging to the Rutaceae and Annonaceae families was conducted using a cell-based HCoV-229E inhibition assay. Due to its significant activity, the ethyl acetate extract of the leaves of Clausena harmandiana was selected for further chemical and biological investigations. Mass spectrometry-guided fractionation afforded three undescribed phenolic lipids (1-3), whose structures were determined via spectroscopic analysis. The absolute configurations of 1 and 2 were determined by analyzing Mosher ester derivatives. The antiviral activity against SARS-CoV-2 was subsequently shown, with IC50 values of 0.20 and 0.05 µM for 2 and 3, respectively. The mechanism of action was further assessed, showing that both 2 and 3 are inhibitors of coronavirus entry by acting directly on the viral particle. Phenolic lipids from Clausena harmandiana might be a source of new antiviral agents against human coronaviruses.
Collapse
Affiliation(s)
- Marion Chambon
- Institut de Chimie des Substances Naturelles, CNRS, UPR 2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Charline Herrscher
- Unité Mixte Processus Infectieux en Milieu Insulaire Tropical, Université de la Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Plateforme Technologique CYROI, 94791 Sainte Clotilde, France
| | - Dana Al Halabi
- Unité Mixte Processus Infectieux en Milieu Insulaire Tropical, Université de la Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Plateforme Technologique CYROI, 94791 Sainte Clotilde, France
| | - Nathan François
- Center for Infection and Immunity of Lille (CIIL), Institut Pasteur de Lille, Université de Lille, INSERM U1019, CNRS UMR 8204, CHU Lille, 59000 Lille, France
| | - Sandrine Belouzard
- Center for Infection and Immunity of Lille (CIIL), Institut Pasteur de Lille, Université de Lille, INSERM U1019, CNRS UMR 8204, CHU Lille, 59000 Lille, France
| | - Stéphanie Boutet
- Institut Jean-Pierre Bourgin (IJPB), AgroParisTech, INRAE, Université Paris-Saclay, 78000 Versailles, France
| | - Van Cuong Pham
- Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, CauGiay, Hanoi 10072, Vietnam
| | - Thi Mai Huong Doan
- Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, CauGiay, Hanoi 10072, Vietnam
| | - Karin Séron
- Center for Infection and Immunity of Lille (CIIL), Institut Pasteur de Lille, Université de Lille, INSERM U1019, CNRS UMR 8204, CHU Lille, 59000 Lille, France
| | - Patrick Mavingui
- Unité Mixte Processus Infectieux en Milieu Insulaire Tropical, Université de la Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Plateforme Technologique CYROI, 94791 Sainte Clotilde, France
| | - Marc Litaudon
- Institut de Chimie des Substances Naturelles, CNRS, UPR 2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| | - Chaker El Kalamouni
- Unité Mixte Processus Infectieux en Milieu Insulaire Tropical, Université de la Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Plateforme Technologique CYROI, 94791 Sainte Clotilde, France
| | - Cécile Apel
- Institut de Chimie des Substances Naturelles, CNRS, UPR 2301, Université Paris-Saclay, 91198 Gif-sur-Yvette, France
| |
Collapse
|
2
|
Andries J, Viranaicken W, Cordonin C, Herrscher C, Planesse C, Roquebert B, Lagrange-Xelot M, El-Kalamouni C, Meilhac O, Mavingui P, Couret D, Gadea G, Despres P. Author Correction: The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech). Sci Rep 2022; 12:6498. [PMID: 35444227 PMCID: PMC9019531 DOI: 10.1038/s41598-022-10885-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Jessica Andries
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Wildriss Viranaicken
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Colette Cordonin
- Plate-Forme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Charline Herrscher
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Cynthia Planesse
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Bénédicte Roquebert
- Laboratoire CERBA, Parc d'activités « Les Béthunes », 95310, Saint-Ouen-l'Aumône, France
| | - Marie Lagrange-Xelot
- Centre Hospitalier Felix Guyon, Centre Hospitalier Universitaire-La Réunion, 97000, Saint-Denis, La Réunion, France
| | - Chaker El-Kalamouni
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Olivier Meilhac
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Patrick Mavingui
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - David Couret
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.,Groupe Hospitalier Sud Réunion, Centre Hospitalier Universitaire-La Réunion, 97410, Saint-Pierre, La Réunion, France
| | - Gilles Gadea
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.,IRCM, U1194, MetaSarc Team, 34298, Montpellier, France
| | - Philippe Despres
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
| |
Collapse
|
3
|
Andries J, Viranaicken W, Cordonin C, Herrscher C, Planesse C, Roquebert B, Lagrange-Xelot M, El-Kalamouni C, Meilhac O, Mavingui P, Couret D, Gadea G, Despres P. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech). Sci Rep 2022; 12:5999. [PMID: 35397679 PMCID: PMC8994064 DOI: 10.1038/s41598-022-10057-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 03/16/2022] [Indexed: 01/07/2023] Open
Abstract
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine comirnaty is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in comirnaty-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from comirnaty vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine comirnaty.
Collapse
Affiliation(s)
- Jessica Andries
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Wildriss Viranaicken
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Colette Cordonin
- Plate-Forme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Charline Herrscher
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Cynthia Planesse
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Bénédicte Roquebert
- Laboratoire CERBA, Parc d'activités « Les Béthunes », 95310, Saint-Ouen-l'Aumône, France
| | - Marie Lagrange-Xelot
- Centre Hospitalier Felix Guyon, Centre Hospitalier Universitaire-La Réunion, 97000, Saint-Denis, La Réunion, France
| | - Chaker El-Kalamouni
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Olivier Meilhac
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - Patrick Mavingui
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France
| | - David Couret
- Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.,Groupe Hospitalier Sud Réunion, Centre Hospitalier Universitaire-La Réunion, 97410, Saint-Pierre, La Réunion, France
| | - Gilles Gadea
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.,IRCM, U1194, MetaSarc Team, 34298, Montpellier, France
| | - Philippe Despres
- Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
| |
Collapse
|
4
|
Abstract
Hepatitis B virus (HBV), an enveloped partially double-stranded DNA virus, is a widespread human pathogen responsible for more than 250 million chronic infections worldwide. Current therapeutic strategies cannot eradicate HBV due to the persistence of the viral genome in a special DNA structure (covalently closed circular DNA, cccDNA). The identification of sodium taurocholate co-transporting polypeptide (NTCP) as an entry receptor for both HBV and its satellite virus hepatitis delta virus (HDV) has led to great advances in our understanding of the life cycle of HBV, including the early steps of infection in particular. However, the mechanisms of HBV internalization and the host factors involved in this uptake remain unclear. Improvements in our understanding of HBV entry would facilitate the design of new therapeutic approaches targeting this stage and preventing the de novo infection of naïve hepatocytes. In this review, we provide an overview of current knowledge about the process of HBV internalization into cells.
Collapse
Affiliation(s)
- Charline Herrscher
- Inserm U1259, Morphogénèse et Antigénicité du VIH et des Virus des Hépatites (MAVIVH), Université de Tours and CHRU de Tours, 37032 Tours, France;
| | - Philippe Roingeard
- Inserm U1259, Morphogénèse et Antigénicité du VIH et des Virus des Hépatites (MAVIVH), Université de Tours and CHRU de Tours, 37032 Tours, France;
- Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, 37032 Tours, France
- Correspondence: (P.R.); (E.B.); Tel.: +33-2-3437-9646 (E.B.)
| | - Emmanuelle Blanchard
- Inserm U1259, Morphogénèse et Antigénicité du VIH et des Virus des Hépatites (MAVIVH), Université de Tours and CHRU de Tours, 37032 Tours, France;
- Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, 37032 Tours, France
- Correspondence: (P.R.); (E.B.); Tel.: +33-2-3437-9646 (E.B.)
| |
Collapse
|
5
|
Herrscher C, Pastor F, Burlaud-Gaillard J, Dumans A, Seigneuret F, Moreau A, Patient R, Eymieux S, de Rocquigny H, Hourioux C, Roingeard P, Blanchard E. Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis. Cell Microbiol 2020; 22:e13205. [PMID: 32216005 DOI: 10.1111/cmi.13205] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 03/04/2020] [Accepted: 03/13/2020] [Indexed: 12/16/2022]
Abstract
Hepatitis B virus (HBV) is a leading cause of cirrhosis and hepatocellular carcinoma worldwide, with 250 million individuals chronically infected. Many stages of the HBV infectious cycle have been elucidated, but the mechanisms of HBV entry remain poorly understood. The identification of the sodium taurocholate cotransporting polypeptide (NTCP) as an HBV receptor and the establishment of NTCP-overexpressing hepatoma cell lines susceptible to HBV infection opens up new possibilities for investigating these mechanisms. We used HepG2-NTCP cells, and various chemical inhibitors and RNA interference (RNAi) approaches to investigate the host cell factors involved in HBV entry. We found that HBV uptake into these cells was dependent on the actin cytoskeleton and did not involve macropinocytosis or caveolae-mediated endocytosis. Instead, entry occurred via the clathrin-mediated endocytosis pathway. HBV internalisation was inhibited by pitstop-2 treatment and RNA-mediated silencing (siRNA) of the clathrin heavy chain, adaptor protein AP-2 and dynamin-2. We were able to visualise HBV entry in clathrin-coated pits and vesicles by electron microscopy (EM) and cryo-EM with immunogold labelling. These data demonstrating that HBV uses a clathrin-mediated endocytosis pathway to enter HepG2-NTCP cells increase our understanding of the complete HBV life cycle.
Collapse
Affiliation(s)
- Charline Herrscher
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France
| | - Florentin Pastor
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France
| | - Julien Burlaud-Gaillard
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France.,Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France
| | - Amélie Dumans
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France
| | - Florian Seigneuret
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France
| | - Alain Moreau
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France
| | - Romuald Patient
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France
| | - Sebastien Eymieux
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France.,Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France
| | | | - Christophe Hourioux
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France.,Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France
| | - Philippe Roingeard
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France.,Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France
| | - Emmanuelle Blanchard
- Inserm U1259 MAVIVH, Université de Tours and CHRU de Tours, Tours, France.,Plate-Forme IBiSA des Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France
| |
Collapse
|
6
|
Pastor F, Herrscher C, Patient R, Eymieux S, Moreau A, Burlaud-Gaillard J, Seigneuret F, de Rocquigny H, Roingeard P, Hourioux C. Direct interaction between the hepatitis B virus core and envelope proteins analyzed in a cellular context. Sci Rep 2019; 9:16178. [PMID: 31700077 PMCID: PMC6838148 DOI: 10.1038/s41598-019-52824-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Accepted: 10/23/2019] [Indexed: 01/01/2023] Open
Abstract
Hepatitis B virus (HBV) production requires intricate interactions between the envelope and core proteins. Analyses of mutants of these proteins have made it possible to map regions involved in the formation and secretion of virions. Tests of binding between core and envelope peptides have also been performed in cell-free conditions, to study the interactions potentially underlying these mechanisms. We investigated the residues essential for core-envelope interaction in a cellular context in more detail, by transiently producing mutant or wild-type L, S, or core proteins separately or in combination, in Huh7 cells. The colocalization and interaction of these proteins were studied by confocal microscopy and co-immunoprecipitation, respectively. The L protein was shown to constitute a molecular platform for the recruitment of S and core proteins in a perinuclear environment. Several core amino acids were found to be essential for direct interaction with L, including residue Y132, known to be crucial for capsid formation, and residues L60, L95, K96 and I126. Our results confirm the key role of L in the tripartite core-S-L interaction and identify the residues involved in direct core-L interaction. This model may be valuable for studies of the potential of drugs to inhibit HBV core-envelope interaction.
Collapse
Affiliation(s)
- Florentin Pastor
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France
| | - Charline Herrscher
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France
| | - Romuald Patient
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France
| | - Sebastien Eymieux
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France
| | - Alain Moreau
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France
| | - Julien Burlaud-Gaillard
- Plate-Forme IBiSA des Microscopies, PPF ASB - University of Tours and CHRU of Tours, Tours, France
| | - Florian Seigneuret
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France
| | | | - Philippe Roingeard
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France. .,Plate-Forme IBiSA des Microscopies, PPF ASB - University of Tours and CHRU of Tours, Tours, France.
| | - Christophe Hourioux
- INSERM U1259 MAVIVH - University of Tours and CHRU of Tours, Tours, France. .,Plate-Forme IBiSA des Microscopies, PPF ASB - University of Tours and CHRU of Tours, Tours, France.
| |
Collapse
|